

10/587578

IAP11 Rec'd PCT/PTO 28 JUL 2006
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Gosse B. Bruinsma

Serial No.: To be assigned

Filed: July 28, 2006

For: METHODS FOR TREATMENT OF
COMPLICATIONS OF DIABETES

Confirmation No.: To be assigned

Examiner: To be assigned

Group Art Unit: To be assigned

Attorney Docket No.: 3154-6270.1US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EV826301340US

Date of Deposit with USPS: July 28, 2006

Person making Deposit: Wendy Neff

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of any cited foreign patents, publications, or pending unpublished U.S. applications are enclosed pursuant to 37 C.F.R. § 1.98(a)(2).

Attorney Docket No.: 3154-6270.1US

U.S. Patent Documents

<u>U.S. Patent No.</u>	<u>Publication Date</u>	<u>Patentee</u>
US - 5,378,723	01-03-1995	Brossi et al.

Other Documents

PCT International Search Report, PCT/US05/02559, dated April 29, 2005.

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, Applicants hereby identify the following listed copending applications naming a common inventor(s):

Attorney Docket No.: 3154-6371.1US
Serial No.: 10/386,915
Filed: 3/12/2003
Title: METHOD FOR TREATING COGNITIVE DISORDERS

Attorney Docket No.: 3154-6288.1US
Serial No.: 11/059,191
Filed: 2/15/2005
Title: COMBINATORIAL THERAPY WITH AN
ACETYLCHOLINESTERASE INHIBITOR AND
(3aR)-1,3a,8-TRIMETHYL-1,2,3,3a,8,8a-HEXAHYDROPYRROLO
[2,3-b]INDOL-5-YL PHENYLCARBAMATE

Attorney Docket No.: 3154-6430.1US
Serial No.: 11/142,644
Filed: 6/1/2005
Title: TRANSDERMAL DELIVERY SYSTEM FOR TREATMENT OF
COGNITIVE DISORDERS

Attorney Docket No.: 3154-6298.1US
Serial No.: 11/147,538
Filed: 6/8/2005
Title: METHODS OF DELAYING ALZHEIMER'S DISEASE
PROGRESSION USING A BETA-AMYLOID PRECURSOR
PROTEIN INHIBITOR AND A HMG COA REDUCTASE
INHIBITOR


10/587578
IAP11 Rec'd PCT/PTO 31 JUL 2006

Attorney Docket No.: 3154-6270.1US

Attorney Docket No.: 3154-6568.1US
Serial No.: 11/261,121
Filed: 10/28/2005
Title: COMPOUND USEFUL IN THE TREATMENT OR PREVENTION
OF COGNITIVE DISORDERS ASSOCIATED WITH DIABETES
AND ASSOCIATED METHODS

This Information Disclosure Statement is filed within three (3) months of the filing date of the above-identified application, and no certification pursuant to 37 C.F.R. § 1.97(c) or a fee pursuant to 37 C.F.R. § 1.17(p) is required.

Respectfully submitted,



Allen C. Turner
Registration No. 33,041
Attorney for Applicant
TRASKBRITT, P.C.
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: July 28, 2006
ACT/alb

Enclosures: Form PTO/SB/08
Cited Non-U.S. Patent Documents
Document in ProLaw

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number

To be assigned

Filing Date

July 28, 2006

First Named Inventor

Gosse B. Bruinsma

Group Art Unit

To be assigned

Examiner Name

To be assigned

Attorney Docket Number

3154-6270.1US

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Commissioner for Patents, Washington, DC 20231.

10/587578
IAP11 Rec'd PCT/PTO 31 JUL 2006¹

PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	To be assigned
Filing Date	July 28, 2006
First Named Inventor	Gosse B. Bruinsma
Group Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	3154-6270 IUS

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		PCT International Search Report, PCT/US05/02559, dated April 29, 2005.	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.